Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 1.56 Billion |
| Market Size (2027) | USD 1.62 Billion |
| Market Size (2032) | USD 1.93 Billion |
| Growth Rate (2027 - 2032) | 3.60 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Middle East and Africa Alpha-Glucosidase Inhibitors Market Analysis by Mordor Intelligence
The Middle East And Africa Alpha-Glucosidase Inhibitors Market size is projected to be USD 1.56 billion in 2026, USD 1.62 billion in 2027, and reach USD 1.93 billion by 2032, growing at a CAGR of 3.60% from 2027 to 2032.
The COVID-19 outbreak increased attention toward comprehensive diabetes management across the Middle East and Africa, leading to greater monitoring of glycemic parameters among high-risk patient populations. Alpha-glucosidase inhibitors maintained their clinical relevance in the region due to their effectiveness in controlling postprandial blood glucose levels, particularly when used alongside other oral antidiabetic therapies. As healthcare systems prioritized diabetes care continuity during the pandemic, demand for established glucose-lowering therapies, including alpha-glucosidase inhibitors, remained resilient across several regional markets.
The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Over the past few decades, african countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. More than 70% of the global population with diabetes resides in developing countries. The africans anticipated to experience considerable growth due to a more geriatric population and rising prevalence of diabetes mainly due to the enhanced stress level, sedentary lifestyles, smoking, and excessive consumption of alcohol that elevates the body's sugar levels have led to the growth of the market.
This is driving the demand for Alpha-Glucosidase Inhibitors Market in Middle-East and Africa, thereby driving the market in focus during the forecast period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Market Trends and Insights
Rising Diabetes Prevalence in Middle East and Africa Region
Type-1 diabetes accounts for approximately 10% of diabetes cases in the Middle East and Africa, while type-2 diabetes accounts for 90%. Type-1 diabetes patients must take insulin for the rest of their lives while also eating a healthy diet and exercising regularly. Type-2 diabetes patients must eat healthily, stay physically active, and have regular blood glucose tests. They may also need to take oral medication and insulin to keep their blood glucose levels under control. Diabetes has many complications, including diabetic ketoacidosis and nonketotic hyperosmolar coma. Heart disease, stroke, kidney failure, foot ulcers, and eye damage are all serious long-term complications. Despite extensive research on COVID-19, only a few Middle Eastern and African countries focused on the epidemiology of COVID-19 among diabetic patients and its implications. We emphasize the critical importance of conducting a thorough study to fully understand COVID-19 and its relationship to diabetes in order to develop and implement evidence-based initiatives and policies in the Middle East and Africa.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and Africa region.
Saudi Arabia and Egypt is Expected to Dominate the Middle East and Africa Alpha-Glucosidase Inhibitors Market.
The country faces a growing burden of diabetes. Saudi Arabia is ranked among the top three Middle Eastern and African countries with the highest prevalence of diabetes. Saudi Arabia is aiming to reduce the prevalence of the disease by 10% over the next decade. The government is taking on a number of initiatives to stop the epidemic from spreading, such as taxing sugary drinks, promoting physical fitness, and emphasizing preventative care. The government's focus on combating diabetes and the higher purchasing power of the people in the country may help the market for diabetes drugs, like insulin drugs, during the forecast period.
The government has been working on plans and policies to control the outcome of diabetes. For instance, the Saudi government announced in July 2022 that Saudi Arabia saw growing demand for quality healthcare services spurred by changes, including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
Competitive Landscape
Market Concentration
The Middle East and Africa alpha-glucosidase inhibitors market studied is fragmented by the presence of manufacturers like Bayer, SunPharma, Pfizer, and Takeda etc.
Middle East and Africa Alpha-Glucosidase Inhibitors Industry Leaders
-
Takeda
-
Pfizer
-
Bayer
-
SunPharma
-
Glenmark
- *Disclaimer: Major Players sorted in no particular order
Middle East and Africa Alpha-Glucosidase Inhibitors Market Companies Covered in this Report
- Bayer
- Takeda Pharmaceuticals
- Pfizer
- Glenmark Pharmaceuticals
- Sun Pharmaceuticals Industries
- Torrent Pharmaceuticals
- Unichem
- Hexalag
Read Analysis of Middle East and Africa Alpha-Glucosidase Inhibitors Companies
Recent Industry Developments in Middle East and Africa Alpha-Glucosidase Inhibitors Market
- April 2023: A study was planned to move towards drug repurposing by utilizing Food and Drug Administration (FDA)-approved drugs against glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing clashes to find the potential inhibitor against glucosidase.
- July 2022: The drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA) of India, fixed the prices of 84 drug formulations, including those used for the treatment of diabetes. According to the order, a single tablet of Voglibose was anticipated to cost Rs 10.47 (USD 0.13), excluding GST.
Middle East and Africa Alpha-Glucosidase Inhibitors Market Report Scope
Inhibitors of alpha-glucosidase prevent the small intestine from absorbing carbohydrates. They compete with one another to prevent the enzymes that change complicated, non-absorptive carbohydrates into simple, absorbable ones. The glucoamylase, sucrase, maltase, and isomaltase enzymes are among them. The Middle East and Africa alpha-glucosidase inhibitors market is segmented by geography (Iran, Saudi Arabia, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
Segmentation Overview
Drug
| Alpha-glucosidase Inhibitors |
Geography
| South Africa |
| Saudi Arabia |
| Oman |
| Egypt |
| Iran |
| Rest of Middle-East and Africa |
| Drug | Alpha-glucosidase Inhibitors |
| Geography | South Africa |
| Saudi Arabia | |
| Oman | |
| Egypt | |
| Iran | |
| Rest of Middle-East and Africa |
Key Questions Answered in the Report
What is the current Middle East and Africa Alpha-Glucosidase Inhibitors Market size?
The Middle East & Africa Alpha-Glucosidase Inhibitors Market is expected to grow from USD 1.62 billion in 2027 to USD 1.93 billion by 2032, at a CAGR of 3.60% during the forecast period. The market was valued at USD 1.56 billion in 2026.
Who are the key players in Middle East and Africa Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, SunPharma and Glenmark are the major companies operating in the Middle East and Africa Alpha-Glucosidase Inhibitors Market.
What years does this Middle East and Africa Alpha-Glucosidase Inhibitors Market cover?
The report covers the Middle East and Africa Alpha-Glucosidase Inhibitors Market historical market size for years: 2021, 2022, 2023, 2024, 2025, and 2026. The report also forecasts the Middle East and Africa Alpha-Glucosidase Inhibitors Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.